Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegfilgrastim-qilo
- Development stage
- Approved
- Lead developer
- Qilu Pharmaceutical
- Administration
- Subcutaneous
01
Overview
The designation "pegfilgrastim-qilo" is not an officially recognized or confirmed non-proprietary name or biosimilar-specific suffix in major regulatory databases (e.g., FDA, EMA). However, Qilu Pharmaceutical Co., Ltd. (a Chinese pharmaceutical company) is known to be developing or marketing a biosimilar version of pegfilgrastim. This biosimilar, like reference pegfilgrastim, is expected to be a PEGylated form of recombinant human granulocyte colony-stimulating factor (G-CSF) designed to stimulate the production, maturation, and activation of neutrophils. The accurate official name for Qilu's pegfilgrastim biosimilar is not "pegfilgrastim-qilo" based on current public records.
- Brand names
- NeulastaFulphilaFylnetraNyvepriaStimufendUdenycaZiextenzoCegfilaGrasustekPelgrazPelmegLapelga
- Other names
- Qilu pegfilgrastim biosimilar
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on pegfilgrastim-qilo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegfilgrastim-qilo.